1286317-53-0

Basic information

• Product Name: AcetaMido,N-(3R)-piperidinyl
• Synonyms: AcetaMido,N-(3R)-piperidinyl;N-[(3R)-piperidin-3-yl]acetamide
• CAS NO: 1286317-53-0
• Molecular Formula: C7H13N2O *
• Molecular Weight: 141.19092
• Mol File: 1286317-53-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AcetaMido,N-(3R)-piperidinyl(CAS DataBase Reference)
• NIST Chemistry Reference: AcetaMido,N-(3R)-piperidinyl(1286317-53-0)
• EPA Substance Registry System: AcetaMido,N-(3R)-piperidinyl(1286317-53-0)

Safety Data

• Hazardous Substances Data: 1286317-53-0(Hazardous Substances Data)

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 5867-45-8 N-(pyridin-3-yl)acetamide 
• 129888-60-4 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)piperidine 
• 129888-61-5 3-Azido-1-(tert-butoxycarbonyl)piperidine 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 6859-99-0 3-hydroxypiperazine 
• 129888-62-6 N-(1-tert-butoxycarbonyl-3-piperidyl)acetamide 

Downstream Products

• 334618-23-4 3-(R)-aminopiperidine dihydrochloride 
• 60407-35-4 1-phenylmethyl-3-aminopiperidine 
• 74045-92-4 N'-(1-benzyl-3-piperidinyl)-N-(2-chloroethyl)urea 
• 307532-02-1 3-amino-1-benzylpiperidine dihydrochloride 

Relevant articles and documents

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME

The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): wherein R1, R2 and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.

Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.

Nitrosourea derivatives 18-22 which utilize either a piperidine or pyridine ring as a carrier group were synthesized and evaluated for anticancer activity. N'-(1-Benzyl-4-piperidinyl)-N-(2-chloroethyl)-N-nitosourea hydrogen maleate (19) exhibited good activity against intracranial L1210 leukemia as well as the mouse ependymoblastoma brain tumor system. Compound 19 exhibited comparable activity in the Lewis lung carcinoma system to N,N'-bis(2-chloroethyl)-N-nitrosourea. Replacement of the N-benzyl group in both the 3-piperidinyl- and 4-piperidinylnitrosoureas resulted in less active compounds in all tumor systems tested. The 3-pyridylnitrosourea 22 was inactive in the L-1210 leukemia system.